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Abstract. Neurodegenerative diseases such as
Alzheimer’s disease (AD), Parkinson’s disease (PD)
and Huntington’s disease (HD) are increasing in
prevalence and the need for novel disease-modifying
therapies is critical. Identifying compounds that
modify disease progression has been a struggle -
mainly due to the insufficient knowledge regarding
the underlying pathophysiological mechanisms of these
diseases. Traditional high-throughput screening in
vitro have previously identified positive hits. However,
subsequent validation experiments in vivo, rendered
them ineffective and/or toxic. Drosophila models of
neurodegenerative disease can be effectively exploited
in drug screens for the identification of compounds and
target disease mechanisms. This review sheds light
on how Drosophila models of neurodegeneration can
aid the therapeutic discovery process through the use
of chemical and genetic suppressor/enhancer screens
and other existing techniques. Integrating Drosophila
models of neurodegeneration to the drug discovery
process holds great promise for the enhanced rate of
therapeutic-modifying compound discovery.
Keywords Drosophila – fruit fly – drug discovery –
neurodegeneration – Alzheimer’s disease – Parkinson’s
disease – Huntington’s disease.
1 Introduction
Drug discovery is the process by which new candidate
compounds and molecules that have a therapeutic ef-
fect on disease symptoms are discovered. Traditionally,
the process of drug discovery begins with identifying
a disease-causing protein, followed by a screening of a
large library of known chemical compounds in order to
identify drugs that ameliorate or alter the function of
the disease-causing proteins. Subsequently, compounds
are optimized and then testedin animal models (Pandey
and Nichols, 2011). The traditional high-throughput
screening (HTS) approach has been the source of many
documented successes, ranging from identifying ther-
apeutic compounds to cell functions and pathological
pathways (Giacomotto and Se´galat, 2010). However,
despite the numerous triumphs brought about by HTS,
the past couple of year shave seen a slow-down in the
development of new therapeutic drugs, due to a variety
of reasons, mainly the positive hits generated by initial
screening are being rendered invalid when tested in an-
imal models and therapeutically ineffective when tested
on humans; furthermore, the method depends on pre-
determined targets and therefore, does not leave space
for new target discovery (Giacomotto and Se´galat, 2010;
Lindsay, 2003).
Lately, there has been an increased interest in target
discovery. The identification of novel targets and early
validation techniques will help reduce subsequent failure
rates of positive hits,and address the problems being
faced by the pharmaceutical companies (Lindsay, 2003).
The limited predictive value of HTS for clinical outcome
can be overcame with the use of animal models for a
primary drug screening platform (Pandey and Nichols,
2011).
Drosophila melanogaster is one such organism that
is gaining momentum as a valid screening tool for the
drug discovery process (Lieschke and Currie, 2007).
Drosophila has been used since the 20th century and
provides the advantage of combing genetic acquiescence
and a rapid lifecycle. In addition, culture conditions
are compatible with large-scale screening and their use
permits high-throughput screening in a whole animal
context which is not dependent on a predetermined tar-
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get (Giacomotto and Se´galat, 2010). Another advan-
tageous aspect to keep in mind is that key biological
features are conserved from the flies to humans, includ-
ing a highly structured brain, elaborate neuromuscu-
lar junctions, and underlying mechanisms of synaptic
transmission. This context provides a good foundation
for developing an appropriate model for human disease
characterising the pathological phenotype (Lenz et al.,
2013). Screening for novel drugs in Drosophila enables
the selection of high-quality hits that display keys fea-
tures such as transdermal availability, metabolic stabil-
ity and low toxicity (Pandey and Nichols, 2011). This
in turn reduces the expenses spent on primary screen-
ing and filters the quality of positive hits for secondary
screening.
2 Why The Fly?
2.1 Brief history of the fly
Drosophila is an old player in the biomedical field with
a rich history spanning over 100 years. Fruit flies have
been indirectly associated with medical progress and
drug discovery for many years, mainly through genetic,
biochemical and disease pathology-related discoveries
(Se´galat, 2007). Indeed, Nobel prizes have been awarded
to people for their pioneering research in flies, starting
with Thomas Hunt Morgan for the role of chromosomes
in heredity (1933), Hermann Muller for the production
of mutations by x-rays (1946), Edward B. Lewis, Chris-
tiane Nusslein-Volhard and Eric F. Wieschaus for ge-
netic control of early structural development (1995) and
finally Jules Hoffman for the discoveries around innate
and adaptive immunity (2011).
In the modern era, Drosophila was amongst first com-
plex organisms to have its entire genome sequenced
(Adams et al., 2000). A couple of years later when the
human genome was sequenced, the observed homolo-
gies between the two genomes was recognised and this
strengthened its role as a model to understand disease
processes (Pandey and Nichols, 2011). Recently, their
use as direct HTS tools gained momentum mainly due to
their unique life cycle, form, function and experimental
manipulation (Rand, 2010).
2.2 Basic biology of the fly
Flies are reared in small vials on a simple solid food
medium of cornmeal, yeast and agar. At the optimum
temperature of 25 ◦C their generation time is 10-11 days
from egg to adult (Rand, 2010). The fly has a very
rapid lifecycle which is comprised of four distinct stages:
embryo, larva, pupa and adult. Each stage presents a
unique opportunity to assess the susceptibility to the
nervous system to xenobiotics (Rand, 2010). The em-
bryo stage lasts around 24 hours at 25 ◦C and during
this time neurogenesis and differentiation give rise to
a fully functioning nervous system, capable of sensory
and motor behaviours characteristic to the larva (Rand,
2010). In fact, the embryo is typically used in devel-
opmental studies examining pattern formation, cell fate
determination, organ formation, neuronal development
and axon guidance (Pandey and Nichols, 2011). The
larval stage lasts over 4 days and is characterised by
a period of growth that results in a 10-fold increase in
body size (Truman and Bate, 1988). The larva is used
to study physiological processes and simple behaviours
like foraging (Pandey and Nichols, 2011). The following
5-6 days of pupal metamorphosis is characterised by tis-
sue reorganisation and the fusing together of the adult
structures from the precursor imaginal disc tissues. At
the same time, the central and periphery nervous system
neurons undergo pruning and regrowth while newly born
adult neurons migrate to their final position and ex-
tend their synapses to their targets (Williams and Tru-
man, 2004). The emerged adult fly is a complex organ-
ism capable of showing behaviours like flight, chemo-,
photo- and geo-taxis, foraging and mating (Rand, 2010).
The brain of the adult fly has more than 100,000 neu-
rons that form discreet circuits and mediate complex
behaviours including circadian rhythms, sleep, learning
and memory, courtship, feeding, aggression, grooming,
and flight navigation (Pandey and Nichols, 2011) (Fig-
ure 1).
2.3 Genetic Workhorse
Drosophila has been primary regarded as a model for
the study of genetics. The first genetic principles of
chromosomal heredity and mutagenesis, were primary
discovered using the fly (Rubin and Lewis, 2000). The
large polytene chromosomes served as a template for
gene mapping and the mutagenesis screens rapidly ad-
vanced the knowledge of gene function. The fly has a
relatively simple genetic make-up of four chromosomes
encoding roughly 13,600 genes (half the number found
in humans) (Adams et al., 2000). More than 95 % of
its genetic content is on three of its four chromosomes,
with the first being the sex chromosome and the other
three being the autosomes (Rand, 2010). The sequence
identification of genes brought about by the emergence
of molecular cloning and recombinant DNA technol-
ogy, opened doors to functional analysis of transgenes
in vivo (Rand, 2010). The method of creating trans-
genic flies through transposable element transformation,
opened the door to manipulating the expression of en-
dogenous or exogenous genes over the course of develop-
ment and provided a means of integrating foreign DNA
into the chromosome (Duffy, 2002). Variations in the
method has led to the creation of the “workhorse” of
fly transgenic models, the Gal4-UAS gene expression
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Figure 1: Drosophila as a model organism.(a) The arthropod Drosophila fits on a pencil tip and can be easily kept in the
laboratory. Their anatomy displays characteristic features that can be used as phenotypes to study neurodegeneration and
as endpoints in high-throughput screening. (b) Confocal image of a cross-section through the adult Drosophila head; auto-
immunofluorescence visualises the ommatidia of the compound eye (CE), the optic lobe (OL) and the central brain (CB). The
cell bodies (arrowheads) are topologically separated from axonal extensions which make up the neuropil. (c) Confocal image of
a whole mount adult brain immunolabelled with anti-nc82 which recognises the Bruchpilot protein that is specifically enriched
in active zones of synaptic terminals. This allows the visualisation of cortical areas in the fly brain, including optic lobes (OL),
antennal lobes (AL), superior protocerebrum (SP), lateral protocerebrum (LP), mushroom bodies (MB), deuterocerebrum (D),
and subesophageal ganglion (SG) (adapted from Hirth (2010)).
system (Duffy, 2002). This bipartite approach keeps
the yeast transcription factor Gal4 and the Upstream
Activating Sequence (UAS) promoter (which holds the
transgene) to which Gal4 binds, on different parental
strains. When the two strains are mated, the progeny
expresses the transgene in the specific tissues defined by
the Gal4 driver (Pandey and Nichols, 2011). Other mod-
ifications and enhancers further refined tissue specificity
as well as temporal expression specificity (McGuire et
al., 2004). This methodology has been crucial in creat-
ing “humanized” versions of the flies that express disease
genes that invoke neuropathology mimicking human dis-




The genetic advantages and tools that come with the
use of Drosophila make it very easy to rapidly generate
models of human disease, which can be used for ther-
apeutic target discovery. The generation of Drosophila
models that express human genes is a popular approach
for studying neurodegenerative diseases. Fly models for
neurodegenerative diseases have been generated, stud-
ied and used for many years. Neurodegenerative dis-
eases are considered to be predominately diseases that
occur at an older age, implying that processes that are
altered due to aging may contribute to their pathogene-
sis (Newman et al., 2011). They are characterised by the
misfolding, aggregation and deposition of normal or ab-
normal proteins that become aberrant (Newman et al.,
2011). Many late-onset neurodegenerative diseases are
generally associated with the formation of intracellular
aggregates of toxic proteins (Taylor et al., 2002). The
common hypothesis is that neurodegenerative diseases
come about when the production of neurotoxic proteins
exceeds the cell’s capacity for clearing them or when
they evade autophagic clearance altogether (Pandey and
Nichols, 2011).
3.1 Parkinson’s disease
PD is a progressive, disabling, heterogeneous neurode-
generative disorder that clinically presents with motor
and non-motor features (Henchcliffe et al., 2011). PD
is characterized by loss of dopaminergic neurons in the
substantia nigra and formation of filamentous intraneu-
ronal inclusions (Lewy bodies [LBs]) (Feany and Bender,
2000). The major components of LBs are amyloid fib-
rils of the protein α-synuclein (Spillantini et al., 1998).
Mutations in the α-synuclein gene (SNCA) are associ-
ated with familial PD and have an increased aggregation
propensity in vitro (Conway et al., 2000; Greenbaum
et al., 2005). Overexpression of human α-synuclein in
different model systems, have provided a pathologically
true model of PD. In several of these models, the rate
of fibril and inclusion body formation does not corre-
late with neurotoxicity (Chen and Feany, 2005; Volles
and Lansbury, 2007). This lack of correlation formed
the basis for the hypothesis that small oligomers, but
not fibrils, are the most toxic species of α-synuclein
(Lashuel and Lansbury, 2006). One great advantage of
using Drosophila to model PD is their ability to reprise
some of the key neuropathological characteristics of PD.
Transgenic flies show age-dependent, progressive degen-
eration of dopamine neurons, inclusion-like formation,
progressive locomotor deficits and a decrease in lifespan
(Muqit and Feany, 2002).
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3.2 Alzheimer’s disease
Alzheimer’s disease is the most prevalent form of se-
nile dementia in humans, with its manifestation being
age-dependent and its incidence in the general popula-
tion expected to rise from 6 % to 30 % over the next
65 years (Puglielli et al., 2003). AD is diagnosed by
the presence of neuritic plaques, composed mainly of
AB peptides and neurofibrillary tangles composed of tau
protein (Finelli et al., 2004). There is evidence that the
B-amyloid peptides are central to the pathogenesis of
AD (Crowther et al., 2006). These peptides are gener-
ated by B- and G-secretase cleavage of amyloid precur-
sor protein (APP) to yield peptides of either 40 or 42
amino acids (AB1−40 or AB1−42) (Crowther et al., 2006).
Recently, studies have shown that monomeric peptides
are not toxic but that oligomeric peptides gain toxicity
that is subsequently lost when mature fibres are formed
(Lashuel and Lansbury, 2006). In order to understand
the pathway of neurodegeneration in AD, a faithful ani-
mal model is required. Current mouse models have suc-
cessfully recapitulated AD-like phenotypes (Crowther et
al., 2006; Hsiao et al., 1996). Despite this, mouse mod-
els are laborious to characterize and develop. Drosophila
models of AD drive the expression of the AB peptides in
temporal and tissue specific manner. Several fly mod-
els of AD have been made, including ones expressing
Arctic AB peptides (E693G; an aggressive mutation for
the AD model) and show progressive neurodegeneration,
amyloid deposits, reduction in lifespan and locomotor
dysfunction (Crowther et al., 2006; Sofola et al., 2010;
Iijima et al., 2004; Finelli et al., 2004).
3.3 Huntington’s Disease
A large and diverse group of neurodegenerative dis-
eases are characterised by the abnormal function of
long tracks on tri-nucleotide repeats. The repeats
can be of two kinds; part of the protein-coding se-
quences which result in the production of long stretch
of polyglutamine-containing (polyQ) peptides or in non-
coding sequences (Konsolaki, 2013). Huntington’s dis-
ease (HD) is associated with expanded polyQ repeats in
the gene Huntington within exon 1. Translated stretches
of polyglutamines disrupt cellular processes including
nucleolar stress, the functions of miR34 (its disruption
is linked to the occurrences of some types of cancer), au-
tophagic processes involved in the immune system and
the Akt/GSK3b pathway (involved in cellular growth)
(Konsolaki, 2013). In addition, a form of mutant Hunt-
ington may interfere with specific components of tran-
scriptional machinery in early stages of HD (Cui et al.,
2006).
Mutant Huntington is expressed ubiquitously but se-
lective cell loss is observed in the brain (Vonsattel and
DiFiglia, 1998). In clinical settings, HD is characterised
by involuntary movements and psychiatric disturbances
(Vonsattel and DiFiglia, 1998). Due to the fact, that
polyglutamine diseases are brought about by single-gene
defects (e.g. Huntington gene in HD), Drosophila mod-
els are commonly used to study this neurodegenera-
tive disease. Pathological hallmarks of HD, such as
intracellular and cytoplasmic aggregates of expanded
Huntington are present in Drosophila models of HD
(Pandey and Nichols, 2011). Drosophila models can
be generated through the expression of truncated wild-
type and mutant forms of Huntington, however, it has
been noted that increased polyQ expression leads to in-
creased severity of degeneration, age-dependent degen-
eration and repeat length-dependent protein aggrega-
tion in Drosophila models (Spada and Taylor, 2010).
These models have provided a platform to demonstrate
that human disease genes can yield parallel neurode-
generative effects in Drosophila models (Pandey and
Nichols, 2011).
4 Drug Discovery Takes Flight
4.1 Drug delivery
The mode of drug or compound delivery is an impor-
tant aspect to take into consideration when performing
drug discovery screens (Figure 2). Exposure of the com-
pound to the cells or organs of interest in flies can take a
variety of forms depending on the developmental stage
of the fly. For embryos, drugs can be administered via
maternal feeding, injection or in vitro incubation (Rand,
2010). Due to the unknown metabolic and delivery
characteristics of the embryo, maternal feeding requires
the determination of the experimental dosage (Rand,
2010). Embryo injection methods have recently been
optimized for use in high-throughput screens using an
automated system based on microelectromechanical sys-
tems injectors, which allows successful mass-injections
of Drosophila embryos (Zappe et al., 2006). Chemical
exposure through in vitro incubation of fly embryos has
been effective, however, one limitation of this system is
the permeabilization of the vitelline membrane of the
Drosophila egg chamber (Rand, 2010). For larva and
adult flies, drugs can be supplied through dosages in
food media (Peng et al., 2009). For longer exposures,
the drug can be mixed in the solid media and the larva
can be reared on it; when shorter exposure to the drug
is required, the compound can be diluted and mixed in
a yeast paste (Pandey and Nichols, 2011). Drugs (e.g.
cocaine) have also been successfully delivered to both
larva and adult flies through injection methods (Dimitri-
jevic et al., 2004). The routes for drug administration
in adult flies are numerous. Drugs can be presented as
vapour or aerosols in a controlled environment (Moore
et al., 1998; Parr et al., 2001), in the solid media (Peng
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et al., 2009), from a drug-saturated filter paper (Nichols
et al., 2002), dropped directly onto the exposed nerve
cord of decapitated flies (Torres and Horowitz, 1998), or
injected directly into the fly abdomen (Dzitoyeva et al.,
2003). The route of administration is also dependent
on the taste of the drug being administered: if the drug
has a poignant smell the flies might not eat it. If in-
gesting the drug is the route of administration chosen,
then it might be necessary to introduce the drug to the
fly through a rewarding substrate (e.g. yeast, sucrose or
banana) (Pandey and Nichols, 2011).
Figure 2: Routes for drug administration for drug deliv-
ery in Drosophila. For larva (top), drug can be directly in-
jected or drug can be mixed with media. Media can be either
solid or liquid with 2 % yeast paste to encourage feeding be-
haviour. Adults can have drug delivered as an aerosol or gas,
as a mixture with food substrate, as a direct application to
exposed nerve cord, or as an injection. Drug administra-
tion through feeding generally has the highest throughput
(Pandey and Nichols, 2011).
Feeding assays can also be performed in order to de-
termine whether the presence of a drug is influencing
food intake. One such assay is based on measuring the
feeding frequency by observing the proboscis-extension.
This method can then be validated by short-term mea-
surements of food dye intake (Wong et al., 2009). When
administering drugs, it is important to keep in mind that
female flies feed more frequently than males and there-
fore, their food intake is higher, a consideration that is
especially important for drug delivery. Flies feed more
often when housed in larger groups, and their feeding
times vary on the time of the day (Wong et al., 2009).
There are also different strategies to be considered when
feeding drugs to adult flies. Firstly, the flies will gener-
ally consume a large amount of food if previously starved
for up to 18 hours. This strategy allows for the observa-
tion of the acute effects of the drugs, however, there is a
significant amount of dosage variability of the ingested
drug and is relatively low-throughput. Secondly, main-
taining flies on drug/food for longer than 24 hours al-
lows for steady-state levels to be achieved before testing.
This method allows high-throughput administration of
the drug across large populations, however, the possibil-
ity of adaptive mechanisms (such as down-regulation of
target genes) to prolonged exposure may occur. When
interpreting the data, it is important to keep in mind
that if the flies are removed from the drug-supplemented
food before being subjected to tests, the rate of drug
elimination may need to be accounted for (Pandey and
Nichols, 2011).
Once the method of administration has been chosen,
the next issue to tackle is the compound concentration
that will be delivered to the flies. A key considera-
tion to take into account are the potential differences in
the pharmacokinetics and pharmacodynamics of com-
pounds and small molecules. These molecules can pro-
duce significant discrepancies in drug levels, tissue dis-
tribution profiles and toxicity, between mammals and
flies (Pandey and Nichols, 2011). Since the target is
not always known and the treatment is usually delivered
through food media, it is difficult to predict the range
of doses that need to administered in order to avoid a
low ineffective concentration, or a high toxic one (Gi-
acomotto and Se´galat, 2010). A conceivable approach
would be to test compounds at several concentrations
and log dilutions, established by existing data and the
chemical properties of the compound. Physiologically
effective concentrations can vary from 0.01 to 100 mM
in the food media, although the commonly used con-
centrations are within the range of 1 to 10 mM (Pandey
and Nichols, 2011; Giacomotto and Se´galat, 2010). The
best approach is to start with high concentrations of the
compounds in the medium, since this will ensure that
a lot of the compounds will display a toxic effect on
the flies and they could be further re-tested at a lower
concentration (Giacomotto and Se´galat, 2010). Despite
this, pilot studies have also been done using three differ-
ent log dilutions of 1 mM, 10 mM and 100 mM in order
to ensure the efficacy of a given assay and that drugs
are being ingested.
4.2 The screening process
Once the drug has been delivered to the fly, the next
step is to screen the flies in an attempt to find hits show-
ing an activity or an affinity on a selected target or in
a disease model (Spring, 2005). This usually involves
an alternation of the pathogenic phenotype that could
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be directly attributed to the administered drug. Tra-
ditional HTS involves massive parallel analysis of the
effects of molecules from a large library of compounds
based on in vitro cell culture, biochemical assays or re-
ceptor binding assays (Pandey and Nichols, 2011) (Fig-
ure 3). This approach has contributed to the discovery
of therapeutically effective compounds, identification of
cellular pathways and pathophysiological mechanisms.
Its ultimate goal is to discover and explain relation-
ships between chemical structures and biological activi-
ties (Giacomotto and Se´galat, 2010). Despite the varied
documented successes, this approach has three major
limitations. Firstly, it provides a biased approach de-
pendent on the existence of detectable targets (Lindsay,
2003). Secondly, most disease mechanisms cannot be re-
produced in vitro due to a difference in the complexity
between cells and multicellular organisms (Giacomotto
and Se´galat, 2010). Thirdly, most of the positive hits
generated by the initial screening, fail to reproduce the
results once tested in organisms such as rodents. The
latter is due to a number of difficulties resulting from
poor absorption, solubility, distribution, metabolism,
excretion and toxicity characteristics, which result in a
waste of funds and efforts and a dead-end for most hits
(Bleicher et al., 2003). One such example is that of a
recent screen of 184,880 novel compounds on Hunting-
ton’s disease (HD) aggregates which led to the identifi-
cation of positive hits, including a number of benzoth-
iazoles that inhibited polyglutamine-mediated aggrega-
tion of toxic and misfolded proteins (Heiser et al., 2002).
In a cell culture model of aggregation, all the primary
hits were found to be toxic to cells, and in an animal
model of HD, none of the compounds were therapeu-
tically effective (Hockly et al., 2006). The advantages
of integrating the fly in the primary screening process
include; cost-effectiveness and high-quality positive hits
to streamline the pool of candidates, before moving on
to secondary screening on expensive mammalian-based
models (Pandey and Nichols, 2011).
Drug discovery studies from models of disease can be
done in two approaches: the disease model can be used
in the chemical enhancer/suppressor drug screens or the
model can be used to further understand the pathologi-
cal processes of the disease and in turn, highlight poten-
tial therapeutic targets. Chemical enhancer/suppressor
(or candidate drug delivery) can be unbiased and they
consist in testing chemical libraries for their ability to
reverse the disease phenotype (Newman et al., 2011).
For this purpose, mutant strains of Drosophila which
mimic human disease and have clear and easy read-
outs of phenotypic modulation, are an attractive pack-
age for medium to high-throughput drug screening (Gi-
acomotto and Se´galat, 2010) (Figure 3). An example of
such a screen is that reported by Zhang et al. (2005),
in which primary screening of a 16,000 compound li-
brary that was done in a yeast model of HD, identi-
fied 4 compounds capable of preventing polyQ aggrega-
tion and toxicity. A cell-based assay and a Drosophila
rough eye phenotype HD model, were then used to test
the anti-aggregation properties of these 4 compounds.
One of them, C2-8 was found to suppress the rough eye
phenotype and polyQ inclusion formation, atrophy and
motor impairment in a rodent model (Chopra et al.,
2007). Several biased candidate drug studies have been
undertaken in Drosophila models of neurodegeneration
in which, compounds were used to interfere with protein
misfolding (Fujikake et al., 2008), aggregation (Apostol
et al., 2003), clearance (Sarkar et al., 2008) and neu-
ronal dysfunction (Steffan and Thompson, 2003) (Table
1).
Drosophila models of neurodegeneration can be
used in two ways to study the underlying patho-
logical characteristics of a disease: unbiased genetic
screens can be used to identify novel players, or ge-
netic/pharmacological manipulation of proteins or path-
ways implicated in the disease can shed light on the
downstream consequences (Newman et al., 2011). In
traditional forward genetic screens, randomly mutage-
nized flies are screened for disturbances of a pre-defined
phenotype or process. The mutagenized flies can be pro-
duced by a chemical mutagen (e.g. ethylnitrosourea)
or mediated mutagenesis through transposon elements
(e.g. P-element and piggyBac) (Lindsay, 2003; Lenz et
al., 2013). Models of disease can be used in this ge-
netic enhancer/suppressor screen by expressing the dis-
ease gene with a random mutant gene, which may or
may not interact and modify the phenotype (Newman
et al., 2011). One such screen involved using transgenic
flies with the AB pathology expressed in the eye, crossed
against 1,963 mutant fly stocks. This screen identified
23 modifiers of the rough eye phenotype including pro-
teins in the secretory pathway, cholesterol homeostasis
pathway, and proteins involved in chromatin structure
and function (Cao et al., 2008). This unbiased screen
identified some pathways and proteins previously impli-
cated in the disease pathology, but more importantly, it
helped shed light on some new participants of the dis-
ease process which can now be targeted for therapeutic
interventions. Strategic expression or pharmacological
manipulation of implicated proteins or pathways, can
help with validating hypotheses about pathogenic mech-
anisms (Newman et al., 2011). The ‘Tau microtubule’
hypothesis is one of the proposed theories to explain
the pathological Tau processes underlying AD. In vitro
cell-based screens produced convincing evidence to sup-
port this theory, however, there was no such evidence in
vivo (Cowan et al., 2010). All aspects of this hypoth-
esis were tested in one in vivo experimental paradigm
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Figure 3: High-throughput screening using Animal Models for Drug Discovery.(1, black lines) A schematic view of the different
stages which came upon a drug discovery process based on traditional HTS. In the absence of target or in complex mechanism
the HTS can hardly be set up. (2, blue line) An alternative approach is utilising phenotypic chemical screens with small animal
models like Drosophila. (3, red line) Identification of hits in these models may reveals new molecular mechanisms and targets.
The target could be further used in traditional HTS. (4), Drosophila may also bridge the gap between traditional high-throughput
screening and validation in mammalian models (adapted from Giacomotto and Se´galat (2010)).
Table 1: Overview of Drosophila Models of Neurodegeneration and their successes in Drug Discovery. B-Amyloid, Beta Amyloid;
HD, Huntington’s Disease; HSP, Heat shock protein; REP, Rough eye phenotype.
using a Drosophila model of tauopathies (Mudher et al.,
2004). Drosophila models of neurodegeneration play an
important role in drug discovery design as they provide
a vital step for the primary screening of drugs in whole
organisms (for examples refer to Table 1).
4.3 Measurable endpoints
Another crucial step which has a profound impact
upon the quality of the information produced from the
screening process, is the output measurements or end-
points (Giacomotto and Se´galat, 2010) (Table 2). The
requirement of HTS makes choosing endpoints a bal-
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ance between the complexity of the measurable outcome
(e.g. behavioural phenotype, changes in morphology or
molecular composition), and the simplicity in detection
and quantification (Rand, 2010). As automated animal
screening is not always possible, identifying and quan-
tifying endpoints usually depends on laborious observa-
tions and manual scoring (Evanko, 2006). Drosophila
screens vary depending on the assay and the degree to
which it can be mechanised (Pandey and Nichols, 2011).
The higher throughput assay depends on the scoring
of visible phenotypes, dead/alive, or a visible marker.
One of the highest throughput quantitative strategies
involves measuring the fluorescent markers in embryos
by flow cytometry (Pulak, 2006). Viability or lethality
in both larval and pupal stages has proven to be a very
effective high-throughput endpoint in toxicology screen-
ing in Drosophila (Christie et al., 1985), together with
measurement of fluorescent markers (e.g. green fluores-
cent protein [GFP]-tagged genes). Medium throughput
endpoints which involve manual scoring techniques in-
clude observation of overt morphological development
(To¨gel et al., 2013), or indication of a rough eye pheno-
type (Pandey and Nichols, 2011). The latter techniques,
despite being medium throughput endpoints are still
able to screen thousands of drugs per week. Neurode-
generative disorders often result in locomotion or be-
havioural defects such as circadian activity, which pro-
duce quantifiable measures of neurodegeneration. Lower
throughput behavioural assays, such as learning, mem-
ory and social interaction assays (including measuring
aggression and courtship), require time to train the flies
and produce a throughput of 25 to 50 drugs per week
(Scott et al., 2002). Lower throughput assays are mostly
used for validation of leads and target determination and
include assays which require a more detailed analysis
of the fly using biochemical techniques such as affinity
chromatography coupled to mass spectrometry, micro-
array technologies, and genome-wide RNA interference
(RNAi) screening or metaboprofiling studies (Sleno and
Emili, 2008; Lindsay, 2003). The challenge that lies
ahead with improving the screening process involves
optimising the sensitivity of quantifiable endpoints for
pathway-specific screening.
5 Considerations and Limita-
tions
Whole-animal screening is a new and useful tool in
the drug discovery processes. Despite this, animal mod-
els do come with their limitations. The profitability of
an animal model of disease lies in its ability to manifest
the relevant disease phenotype, together with the simi-
larity of the underlying pathological changes, to human
disease. Recent analyses point to the conservation of ap-
proximately 77 % of human disease genes in Drosophila
(Reiter et al., 2001). Despite this, nearly all diseases are
multifactorial and involve a variety of interactions from
different genes and complexes, hence, the consequential
ramifications is the failure of animal models to replicate
the human disease gene network (Venter et al., 2001).
An additional limitation to keep in mind is the
fact that Drosophila are surrounded by a thick cuti-
cle that serves as a physical barrier to the penetra-
tion of molecules (Se´galat, 2007). Compounds penetrate
through the animal’s epidermis by both ingestion and
diffusion (Kaletta and Hengartner, 2006). As a result,
the concentration of a given compound within the ani-
mal is never accurately known and it varies, depending
on the chemical properties of the compounds. Conse-
quently, it is close to impossible to determine if a nega-
tive result is due to poor penetration, docking problems
or a true absence of biological activity in the model; on
the other hand, positive results can only be qualitatively
interpreted (Se´galat, 2007). In an unbiased screen, the
target is not known; since the treatment is delivered
through the media, it is difficult to predict the range of
doses which have to be tested. To avoid missing hits, a
feasible approach may be to test compounds at several
concentrations, starting with a high concentration and
then retesting with lower ones (Giacomotto and Se´galat,
2010; Pandey and Nichols, 2011).
The anatomical and molecular differences between
small model organisms and humans with respect to the
metabolism of compounds, may result in the exclusion
of a significant fraction of positive hits (Giacomotto and
Se´galat, 2010). One such example is the anatomical
differences between insects and vertebrates in relation
to the blood brain barrier (BBB). The Drosophila hu-
moral/central nervous system (CNS) is protected from
the open circulatory system through a thin layer of glial-
deprived epithelial cells (Stork et al., 2008). This makes
the BBB in Drosophila much simpler than that of ver-
tebrates, hence resulting in differences between humans
and flies with regards to drug delivery to the brain tis-
sues. The question, ‘how well is the translation from
fly to human?’ still remains due to, pharmacokinetics
and pharmacodynamics of small molecules as well as
species-specific metabolic issues. Some drugs may be
toxic in flies but not in human and vice versa. This can
be due to a difference in metabolism of the drugs across
species. In addition, the biochemical and physiological
differences may lead to significant discrepancies in drug
levels and tissue distribution profiles between mammal
and fly (Pandey and Nichols, 2011). Despite this, the
animal models are likely to reflect a comparative toxic-
ity to mammals, which would substantiate future paral-
lel studies in other invertebrate and vertebrate models
(Rand, 2010).
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Table 2: Throughput endpoints in Drosophila melanogaster models. (adapted from Pandey and Nichols (2011)).
High Throughput Medium Throughput Low Throughput References
Lethality Olfactory Locomotor defect (Pandey and Nichols,
2011)
Body Size Overt morphological develop-
ment
Body wall contraction (Rand, 2010)
Necrotic Patches Rough Eye Phenotype (Retinal
degeneration)
Body wall muscle (Pulak, 2006)
Viability Negative Geotaxis Assay Response to pain (Christie et al., 1985)
Lethality Circadian activity – sleep,
arousal & rest behaviour
Phototaxis (To¨gel et al., 2013)
Visible & Fluorescent Markers Body weight Rotorod Test (Sleno and Emili, 2008)
Flow cytometry Fecundity Electrophysiology (Scott et al., 2002)
Visible phenotypes Aggression Prepulse inhibition (Lindsay, 2003)
Lifespan Assay (dead/alive) Wing expansion behaviour Courtship behaviour
Flight ability Feeding behaviour
Stress test Learning and memory behaviour




Biochemical techniques (i.e. affin-
ity chromatography, mass spectrome-
try, micro-arrays genome wide RNAi
screening & metaboprofiling)
When using Drosophila to model neurodegenerative
diseases that are common in old age, several challenges
can be encountered. Despite the fact that Drosophila is
readily used to address questions about tissue-specific
functional decline and genetic perturbations on ageing,
the techniques used including lifespan and locomotor
analysis can also be fraught with pitfalls if not carefully
applied (He and Jasper, 2014). Some of the suggestions
to keep in mind when modelling ageing in Drosophila
include: careful control of genetic backgrounds due to
the heterosis effect, which generally results in a longer
lifespan in outcrossed animals; proper maintenance of
source cultures with defined larval densities to avoid in-
fection; synchronised populations with controlled mat-
ing status in order to have same-aged flies; gender differ-
ences which account for asymmetric inheritance of mito-
chondrial genomes, hormonal and metabolic differences,
and maternal effects (Tower and Arbeitman, 2009); diet
consisting of a standardized amount of yeast and hydra-
tion in food (Ja et al., 2009); control of temperature,
humidity and circadian light exposure, which can all
have an effect on the ageing process in the flies (He and
Jasper, 2014).
6 Conclusion
Animal models are increasingly being incorporated
into drug discovery screens. Due to their small size, they
provide a more efficient alternative to in vitro screens as
they fulfil the requirements of large-scale screens, whilst
providing a system in which the physiological context is
preserved. Despite this, Drosophila models have some
limitations when it comes to HTS and therefore, they
are only fully exploited when they are integrated in a
mixed approach for drug discovery. For example, a com-
bination of unbiased enhancer/suppressor screens (used
to identify the novel targets), together with subsequent
validation using candidate genetic or pharmacological
tools, has been previously used in AD Drosophila models
(Cao et al., 2008). Another example is the use of phar-
macological agents in order to identify suspected cellu-
lar processes affected by the administered compounds,
followed by genetic validation of the candidate players
(Mudher et al., 2004; Pallos et al., 2008). In conclusion,
Drosophila models of neurodegeneration hold a lot of
promise as they provide not only a way of modelling the
disease mechanism at a subcellular level, but they also
allow for the study of pathological mechanisms through
behavioural consequences. This information can be eas-
ily used for the design of disease-modifying therapeu-
tic drug discovery that can be potentially applied to
treat human conditions. Furthermore, the integration of
Drosophila models in the drug discovery process allows
for the selection of potential therapeutic models with
an improved safety profile earlier in the drug discovery
process, resulting in less funds and time being wasted
on false positive hits. All in all, the future should see
the incorporation of Drosophila in drug discovery strate-
gies increasing drastically, especially within the areas of
neurodegenerative diseases.
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